THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Highlights Therapeutic Solutions International, Inc.

Equities

TSOI

US8833781011

Market Closed - OTC Markets Other stock markets 10:40:04 2024-07-03 am EDT			5-day change	1st Jan Change
0.00085 ^USD	-5.56%		+12.50%	-10.00%

May. 30	Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 30	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 17	CI
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients	Mar. 04	CI
Therapeutic Solutions International, Inc. Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease	Dec. 11	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene	23-10-20	CI
Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils	23-09-29	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Therapeutic Solutions International, Inc. Announces FlorStilbene?? Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer	23-08-21	CI
Allogen Biologics Inc. Successfully Manufactures JadiCell	23-08-16	CI
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene?	23-07-18	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy	23-04-20	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Therapeutic Solutions International Advances Chronic Obstructive Pulmonary Disease Program by Identifying Novel B Regulatory Cell Mechanism of Action for Jadicell Universal Donor Adult Stem Cell	23-03-13	CI
Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using Florstilbene Immune Stimulator Through Res Nova Bio Subsidiary	23-03-06	CI
Therapeutic Solutions International Launches Veltmeyer Institute for Advanced Biologics	23-02-21	CI
Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics	22-12-05	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Therapeutic Solutions International, Inc.

Equities

TSOI

US8833781011

Highlights

Filters